Nichole Tucker | Authors

Nichole Tucker, MA, is the Senior Editor for Targeted Oncology and host of the Targeted Talks podcast. Tucker received her Bachelor of Arts in Mass Communications from Virginia State University and her Master of Arts in Media & International Conflict from University College Dublin.


Pembrolizumab Combo Prolongs Survival in HER2–, Locally Advanced Unresectable or Metastatic Gastric/GEJ Cancers

November 22, 2022

Results from the phase 3 KEYNOTE-859 study show extended overall and progression-free survival in patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal adenocarcinoma treated with pembrolizumab and chemotherapy.

FDA Grants Priority Review to Subcutaneous Epcoritamab for Previously Treated R/R LBCL

November 21, 2022

Based on positive findings from the phase 2 pivotal EPCORE NHL-1, the FDA will conduct a speedy review of the biologics license application for subcutaneous epcoritamab for the treatment of patients with relapsed/refractory large B-cell lymphoma after 2 or more lines of systemic therapy an granted it priority review.

The Road to Overcoming Disparities in Thyroid Cancer Care

November 20, 2022

In an interview with Targeted Oncology, Megan R. Haymart, MD, provided a recap of a symposium at the American Thyroid 2022 Annual Meeting and discussed disparities in thyroid cancer care, as well as potential solutions

Trilaciclib Shows Potential to Lower Chemotherapy-Induced Myelosuppression Episodes in ES-SCLC

November 18, 2022

Real-world evidence from Florida Cancer Specialists & Research Institute shows that trilaciclib may reduce the chance of patients with extensive-stage small cell lung cancer experiencing chemotherapy-induced myelosuppression events.